To further explore the value and significance of inhibiting ENO1 in clinical translation, we investigated whether the ENO1 inhibitor (AP-III-a4) could synergize with BTZ in MM cells, and found that co-administration had synergistic effects simultaneously in vitro and in vivo. This evidence concerns the gene ENO1 and Miyoshi myopathy.